

Substitute for 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known		
				Application Number		12/966,261
				Filing Date		December 13, 2010
				First Named Inventor		Williams et al.
				Art Unit		3769
Examiner Name		Kai Rajan				
Sheet	1	of	6	Attorney Docket Number	CELG-0642	

U. S. PUBLICATION AND PATENT DOCUMENTS				
Examiner Initials	Cite No.	Document Number	Publication or Grant Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number - Kind Code (if known)		
	1	2005/0090425	04-28-2005	Reardan et al.
	2	2005/0216309	09-29-2005	Reardan et al.
	3	2005/0222874	10-06-2005	Reardan et al.
	4	2006/0129433	06-15-2006	Koneru
	5	5,299,121	03-20-1994	Brill et al.
	6	5,594,637	01-14-1997	Eisenberg et al.
	7	5,619,991	04-15-1997	Sloane
	8	5,660,176	08-26-1997	Iliff
	9	5,758,095	05-26-1998	Albaum et al.
	10	5,832,449	11-03-1998	Cunningham
	11	5,845,255	12-01-1998	Mayaud
	12	5,974,203	10-26-1999	Tadokoro et al.
	13	6,014,631	01-11-2000	Teagarden et al.
	14	6,045,501	04-04-2000	Elsayed et al.
	15	6,055,507	04-25-2000	Cunningham
	16	6,063,026	05-16-2000	Schauss et al.
	17	6,128,620	10-03-2000	Pissanos et al.
	18	6,131,090	10-10-2000	Basso Jr., et al.
	19	6,202,923	03-20-2001	Bayer et al.
	20	6,315,720	11-13-2001	Williams et al.
	21	6,561,976	05-13-2003	Elsayed et al.
	22	6,561,977	05-13-2003	Williams et al.
	23	6,755,784	06-29-2004	Williams et al.
	24	6,767,326	07-27-2004	Elsayed et al.

Examiner Signature	/John Pauls/ (06/29/2012)	Date Considered	06/29/2012
---------------------------	---------------------------	------------------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Substitute for 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	12/966,261
				Filing Date	December 13, 2010
				First Named Inventor	Williams et al.
				Art Unit	3769
Examiner Name	Kai Rajan				
Sheet	2	of	6	Attorney Docket Number	CELG-0642

U. S. PUBLICATION AND PATENT DOCUMENTS				
Examiner Initials	Cite No.	Document Number	Publication or Grant Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number - Kind Code (if known)		
	25	6,869,399	03-22-2005	Williams et al.
	26	6,908,432	06-21-2005	Elsayed et al.
	27	7,141,018	11-28-2006	Williams et al.
	28	7,959,566	06-14-2011	Williams et al.

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T
		Country Code- Number-Kind Code (if known)			
	29	CA 2352619	01-06-2003	Rajewski, Robert	
	30	WO 00/51053	08-31-2000	Gemini Research Ltd.	
	31	WO 02/35440	05-02-2002	Celgene Corp.	
	32	WO 98/13783	04-02-1998	Azron Inc.	
	33	WO 98/58338	12-23-1998	Promedius Systems Inc.	
	34	WO 99/10829	03-04-1999	Lernout & Hauspie Speechprod	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), Volume-issue Number(s), publisher, city and/or country where published.			T
	35	"About the CNR", https://www.clozarilcare.com/care/newUsrReqPersonal.jsp , 1 page			
	36	"Complaint", In the United States District Court District of New Jersey, Case No.: 2:07-cv-00286-PGS-RJH, Filed January 18, 2007, 16 pages			
	37	"Defendant Barr Laboratories Inc.'s Answer, Counterclaims and Demand for Jury Trial", In the United States District Court District of New Jersey, Case No.: 2:07-cv-00286-PGS-RJH, filed March 01, 2007, 67 pages			
	38	"Guide to the Clozaril Patient Monitoring Service", A Reference Manual for the Clozaril Patient Monitoring Service, First Edition, November 1997, 45 pages			

Examiner Signature	/John Pauls/ (06/29/2012)	Date Considered	06/29/2012
--------------------	---------------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Substitute for 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	12/966,261
				Filing Date	December 13, 2010
				First Named Inventor	Williams et al.
				Art Unit	3769
Examiner Name	Kai Rajan				
Sheet	3	of	6	Attorney Docket Number	CELG-0642

NON PATENT LITERATURE DOCUMENTS		
39	"Managing a Product under Attack: A Firsthand report on Colzaril", Medical Marketing & Media, September 20, 1991, 26(10), 8 pages	
40	"Thalomid Information from Drugs.com", June 22, 2006, accessed February 01, 2008, http://www.drugs.com/thalomid.html	
41	Bakken et al., "Local Monitoring Center for Clozapine Therapy: Quality Assurance of Drug Treatment in a Group of Psychiatric Patients", Tidsskr Nor Laegeforen nr., 1998, 118, 1076-1078	
42	Bastani et al., "Development of the Clozaril Patient Management System", Psychopharmacology, 1998, 99, S122-S125	
43	Bates et al., "Effect of Computerized Physician order Entry and a Intervention on Prevention of Serious Medication Errors", The Journal of the American Medical Association, October 21, 1998, 280(15), 1289-1316	
44	Behm, No Title, Am. Pharmacy 13 th APhA Annual Meeting Highlights, 1990, NS30(6), page 7	
45	Bender, "FDA approves reduced clozapine monitoring; increased patient access versus increased risk," Psychiatric Times, 1998, Vol. XV, Issue 5, page 13	
46	Black et al., "A centralized system for monitoring clozapine use in British Columbia," Psychiatric Services, 1996, 47(1), 81-83	
47	Bruera et al., "The uses of psychotropics in symptom management in advanced cancer," Psycho-Oncology., 1998, 7, 346-358	
48	Celgene Corporation, "Thalomid (thalidomide): Balancing the Benefits and the Risks", System for Thalidomide Education and Prescribing Safety, November 1998, 52 pages	
49	Celgene Corporation, "Thalomid (thalidomide): Clinical Information and Prescribing Guidelines", Reference Guide, September 1998, 26 pages	
50	Center for Drug Evaluation and Research Food and Drug Administration, "Forty-Seventh Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee", September 04-05, 1997, 447 pages	
51	Clark et al., "Thalidomide Capsules, A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing," Drug Safety., 2001, 24(2), 87-117	

Examiner Signature	/John Pauls/ (06/29/2012)	Date Considered	06/29/2012
--------------------	---------------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Substitute for 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	12/966,261
				Filing Date	December 13, 2010
				First Named Inventor	Williams et al.
				Art Unit	3769
				Examiner Name	Kai Rajan
Sheet	4	of	6	Attorney Docket Number	CELG-0642

NON PATENT LITERATURE DOCUMENTS		
52	Dimopoulos et al. "Adverse effects of Thalidomide administration in patients with neoplastic diseases," Am. J. Med., October 1, 2004, 117, 508-515	
53	Dunning, "Hoechst Arava Pregnancy Registry Recommended to Track Teratogenicity", The Pink Sheet, August 17, 1998, 60(033), 3 pages	
54	Dunning, "Thalidomide Protocols and Patient Materials designed by FDA for Studies without Commercial Sponsors", The Pink Sheet, November 18, 1996, 58(047), page T&G-4	
55	Fax to Ian Hilley of GenPharm Inc. to John Jackson of Celgene Corp., October 14, 2004, re: Isotretinoin Pregnancy Risk Management Program, 26 pages	
56	Freeman et al., "Will routine therapeutic drug monitoring have a place in clozapine therapy?," Clinical Pharmacokinetics, 1997, 32(2), 93-100	
57	Honigfeld, "Effects of the Clozapine National Registry System on Incidence of Deaths related to Agranulocytosis", Psychiatric Services, January 1996, 47(1), 52-56	
58	Honigfeld, "Reducing clozapine-related morbidity and mortality: 5 years of experience with the clozaril national registry," J. Clin. Psychiatry, 1998, 59(Suppl. 3), 3-7	
59	Janet Woodcock, "Supervisory Review of NDA 20-785", Center for Drug Evaluation and Research, July 07, 1998, 12 pages	
60	Kumar "Clozaril monitoring systems, registry data and analyses," Presentation, Novartis, 2002, 44 pages	
61	Lieberman et al., "A report of clozapine – induced agranulocytosis in the United States (Incidence and risk factors)," Drug Safety, Proceedings of a symposium held in London, 1991, Hoffbrand, A.V, et al. (Eds.), 1-2	
62	Love et al., "Computerized relational database for monitoring clozapine therapy," Am. J. Hosp. Pharm., 1993, 1657-1662	
63	Martin, "APhA says plan continues to interfere with pharmacists' practice prerogatives," Am. Pharmacy, 1991, NS31(5), 30-31	
64	McCullough, "Roche Announces FDA Approval of Enhanced Pregnancy Prevention Program for Accutane", Current News Releases, October 31, 2001, 1 page	
65	Mitchell et al., "A Pregnancy-Prevention Program in Women of Childbearing Age Receiving Isotretinoin", New England Journal of Medicine, July 13, 1995, 333(2), 101-106	
66	Mordue, "Rational approach to clozaril distribution," Am. Pharmacy, 1990, NS30(6), page 7	

Examiner Signature	/John Pauls/ (06/29/2012)	Date Considered	06/29/2012
--------------------	---------------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Substitute for 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	12/966,261
				Filing Date	December 13, 2010
				First Named Inventor	Williams et al.
				Art Unit	3769
				Examiner Name	Kai Rajan
Sheet	5	of	6	Attorney Docket Number	CELG-0642

NON PATENT LITERATURE DOCUMENTS		
67	National Institutes of Health et al, "Thalidomide: Potential Benefits and Risks", Open Public Scientific Workshop, NIH Testimony, http://www.fda.gov/oashi/patrep/nih99.html , September 09, 1997	
68	National Institutes of Health et al, "Thalidomide: Potential Benefits and Risks", Open Public Scientific Workshop, NIH Testimony, http://www.fda.gov/oashi/patrep/nih910.html , September 10, 1997	
69	National Institutes of Health et al., "Thalidomide: Potential Benefits and Risks:", Open Public Scientific Workshop, Program and Abstracts, September 09-10, 1997	
70	Notification Letter dated December 05, 2006 from Sterne Kessler to Celgene Corporation Re: Notification Pursuant to section 505(j)(2)(B)(ii) of the Federal Food, Drug and Cosmetic Act	
71	Notification Letter dated December 15, 2006 from Sterne Kessler to Celgene Corporation Re: Supplemental Notification Pursuant to section 505(j)(2)(B)(ii) of the Federal Food, Drug and Cosmetic Act	
72	Notification Letter dated December 19, 2006 from Sterne Kessler to Celgene Corporation Re: Supplemental Notification Pursuant to section 505(j)(2)(B)(ii) of the Federal Food, Drug and Cosmetic Act	
73	Notification Letter dated October 04, 2007 from Barr Laboratories to Celgene Corporation Re: Supplemental Notification Pursuant to section 505(j)(2)(B)(ii) of the Federal Food, Drug and Cosmetic Act	
74	Oyesanmi et al., "Hematologic side effects of psychotropics," Psychosomatics, 1999, 40, 414-421	
75	Pastuszak et al, "Use of the Retinoid Pregnancy Prevention Program in Canada: Patterns of Contraception Use in Women treated with Isotretinoin and Etretinate", Reproductive Toxicology, 1994, 8(1), 63-68	
76	Patt et al., "Durable Clinical response of refractory hepatocellular to orally administered thalidomide," Am. J. Clin. Oncol. (CCT., 2000, 23(3), 319-321	
77	Peck et al., "FDA's position on the clozaril patient management system," Hospital & Community Psychiatry, 1990, 41(8), 876-877	
78	Richardson et al., "Thalidomide: Emerging role in cancer medicine," Annu. Rev. Med., 2002, 53, 629-657	

Examiner Signature	/John Pauls/ (06/29/2012)	Date Considered	06/29/2012
---------------------------	---------------------------	------------------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.